EUVIMEDEUVIMED entdecken
Kontrollierte klinische Studie

Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial.

Mazyar Zahir, Mohammad Samzadeh, Amirhossien Poopak, Ali Reza Khoshdel, Arash Armin

Urology journal./Urology jornal. · 26.07.2023 · 20 (4) · 255-260

DOI: 10.22037/uj.v20i.7593 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Urology journal./Urology jornal., erschienen am 26.07.2023. Verfasst von Mazyar Zahir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences , Tehran, Iran. mazyar1995@gmail.com. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Sildenafil Citrate, Tadalafil. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To compare the efficacy and adverse events of sildenafil monotherapy for benign prostatic hyperplasia (BPH) with its FDA-approved counterpart, tadalafil. MATERIALS AND METHODS: In this single-arm self-controlled clinical trial, 33 patients were enrolled. All patients underwent a 6-week treatment with sildenafil, followed by a 4-week washout period and finally a 6-week treatment with tadalafil. Patients were examined on each appointment and post-void residual (PVR) urine, International Prostate Symptom Score (IPSS) and Quality of life index (IPSS-QoL index) were recorded subsequently. Efficacy of each drug regimen was then evaluated by comparing these outcome parameters. RESULTS: Both sildenafil and tadalafil were shown to improve PVR (both p < .001), IPSS (both p < .001) and IPSS- QoL index (both p < .001) significantly. Sildenafil was more effective than tadalafil in reducing PVR (mean difference (95%CI) = 9.91% (4.11, 15.72), p < .001) and ameliorating IPSS-QoL index (mean difference (95%CI) = 19.3% (4.47, 34.41), p = .027). Moreover, although not significant, sildenafil reduced IPSS more than tadalafil (mean difference (95%CI) = 3.33% (-0.22, 6.87), p = .065). Concurrent erectile dysfunction did not affect responsiveness to therapy with either sildenafil or tadalafil but age was inversely related to post-treatment IPSS in both sildenafil (B = 0.21 (0.04, 0.37), p = .015) and tadalafil (B = 0.14 (0.02, 0.26), p = .021) regimens with a more prominent role in responsiveness to sildenafil (β = 0.31) compared to tadalafil (β = 0.19). CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaSildenafil CitrateTadalafilHumansMaleErectile DysfunctionLower Urinary Tract SymptomsPhosphodiesterase 5 InhibitorsQuality of LifeTreatment OutcomeUrinary Retention

Substanzen

Phosphodiesterase 5 InhibitorsSildenafil CitrateTadalafil

Autor:innen und Institutionen

  • Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences , Tehran, Iran. mazyar1995@gmail.com.
  • Department of Urology, Islamic Azad University of Tehran Medical Sciences, Tehran, Iran. o_samzadeh@yahoo.com.
  • Tehran University of Medical Sciences, Tehran, Iran . ahpoopak@gmail.com.
  • Professor of epidemiology, Islamic Azad University of Tehran Medical Sciences, Tehran, Iran. alikhoshdel20@gmail.com.
  • Department of Urology, Islamic Azad University of Tehran Medical Sciences, Tehran, Iran. armin.xp@gmail.com.

Zitieren

APA

Zahir, M., Samzadeh, M., Poopak, A., Khoshdel, A. R., & Armin, A. (2023). Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial. Urology journal./Urology jornal., 20(4), 255-260. https://doi.org/10.22037/uj.v20i.7593

Vancouver

Zahir M, Samzadeh M, Poopak A, Khoshdel AR, Armin A. Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial. Urology journal./Urology jornal.. 2023;20(4):255-260. doi:10.22037/uj.v20i.7593

BibTeX
@article{Zahir2023,
  author = {Zahir, Mazyar and Samzadeh, Mohammad and Poopak, Amirhossien and Khoshdel, Ali Reza and Armin, Arash},
  title = {Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial},
  journal = {Urology journal./Urology jornal.},
  year = {2023},
  volume = {20},
  number = {4},
  pages = {255--260},
  doi = {10.22037/uj.v20i.7593}
}
Kostenlos starten →